Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. (Q38820593)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 April 2016

Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas

Language	Label	Description	Also known as
English	Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.	scientific article published on 28 April 2016	Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

phase II clinical trial

0 references

Darren Hargrave

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Monika Warmuth-Metz

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Gudrun Zahlmann

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

T Jaspan

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

P S Morgan

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

M Warmuth-Metz

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

E Sanchez Aliaga

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

D Warren

5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

J Grill

7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

G Zahlmann

10

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

language of work or name

0 references

publication date

28 April 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

American Journal of Neuroradiology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

37

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1581-1587

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Morphological and functional MRI, MRS, perfusion and diffusion changes after radiosurgery of brain metastasis

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Analysis of the layering pattern of the apparent diffusion coefficient (ADC) for differentiation of radiation necrosis from tumour progression.

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

MR imaging of glioblastoma in children: usefulness of diffusion/perfusion-weighted MRI and MR spectroscopy

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

(1)H magnetic resonance spectroscopy in the diagnosis of paediatric low grade brain tumours.

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A4782

21 January 2018

Identifiers

10.3174/AJNR.A4782

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27127006%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38820593&oldid=1505648700"